Drug intelligence / Profile preview

FIC metabolism program

Development stage: Preclinical
Lead developer: Nutshell Therapeutics
Modality: Small Molecules

Overview

Nutshell Therapeutics is developing a small molecule allosteric activator targeting an undisclosed protein, referred to as FIC, for the treatment of metabolic diseases. The program is being advanced using the company's proprietary AI-powered AlloStar™ platform, which is designed to identify and drug allosteric sites on proteins that are traditionally difficult to target with orthosteric ligands. Currently in the IND-enabling stage, this program represents Nutshell's strategic expansion into metabolic indications, leveraging their expertise in allosteric modulation originally established in oncology.

Targets

FICD (FIC domain protein adenylyltransferase)

Beyond the preview

Go deeper on FIC metabolism program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIC metabolism program.

Explore the full profile